SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (79)3/26/2001 12:20:08 PM
From: Biomaven   of 508
 
Good CC - highlight is that ITMN takes responsibility for European trials and regulatory, and gets up to 40% (sliding scale) of profits there. An excellent deal for them - must have been driven by BI realizing that ITMN can get the job done a good few years ahead of BI themselves. Not much in the way of incremental costs to ITMN. Projected to add $0.50 to EPS in '04, rising to $1.50 in '06.

Also good discussion of Actimmune in the US - trial has now enrolled 100 (of 260) patients. Anecdotal reports continue to be good, and they are setting up a registry to formalize these reports.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News